{"id":916,"date":"2013-10-03T17:01:16","date_gmt":"2013-10-03T21:01:16","guid":{"rendered":"http:\/\/blogviejo.sld.cu\/inmuno\/?p=916"},"modified":"2013-10-03T17:01:16","modified_gmt":"2013-10-03T21:01:16","slug":"glycolipids-as-targets-for-tumour-immunotherapy","status":"publish","type":"post","link":"https:\/\/blogs.sld.cu\/inmuno\/2013\/10\/03\/glycolipids-as-targets-for-tumour-immunotherapy\/","title":{"rendered":"Glycolipids as targets for tumour immunotherapy"},"content":{"rendered":"<p><a href=\"http:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2249.2011.04516.x\/full\" target=\"_blank\">Clinical &amp; Experimental Immunology2012;167(2):206\u2013215<\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Clinical &amp; Experimental Immunology2012;167(2):206\u2013215.<\/p>\n","protected":false},"author":125,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[9,29,40],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/posts\/916"}],"collection":[{"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/users\/125"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/comments?post=916"}],"version-history":[{"count":0,"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/posts\/916\/revisions"}],"wp:attachment":[{"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/media?parent=916"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/categories?post=916"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.sld.cu\/inmuno\/wp-json\/wp\/v2\/tags?post=916"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}